Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Prevention of Human Papillomavirus and Vaccines Strategies
share announcement

Prevention of Human Papillomavirus and Vaccines Strategies

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 3147

Special Issue Editor

Prof. Dr. Rui Gil da Costa

E-Mail Website
Guest Editor
Inov4Agro—Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production, Universidade Federal do Maranhao, Sao Luis, Brazil
Interests: GU malignancies; papillomavirus-induced pathologies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Human papillomavirus (HPV) causes the most common sexually transmissible infection worldwide and is associated with benign and malignant lesions of the ano-genital and head-and-neck regions. The development of HPV vaccines is a success story, leading to marked reductions in the incidence of cervical uterine lesions. However, multiple questions regarding HPV prevention remain unanswered, including which strategies might successfully implement vaccination across culturally heterogeneous communities, the extent of its efficacy in preventing specific lesions, how vaccines might be combined with other preventive strategies, and the potential therapeutic efficacy of HPV vaccines against established lesions. This Special Issue welcomes all kinds of contributions, including original research and review articles, on topics related to HPV prevention and vaccination. We expect this Special Issue to be an opportunity to advance scientific knowledge in this field and encourage more effective HPV approaches.

Prof. Dr. Rui Gil da Costa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human papillomavirus
  • HPV vaccines
  • vaccination strategies
  • cervical cancer prevention
  • therapeutic vaccines

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

25 pages, 1633 KiB  
Article
Human Papillomavirus Perceptions, Vaccine Uptake, and Sexual Risk Factors in Students Attending a Large Public Midwestern University
by JaNiese E. Jensen, Linder H. Wendt, Joseph C. Spring and Jay Brooks Jackson
Vaccines 2024, 12(6), 671; https://doi.org/10.3390/vaccines12060671 - 17 Jun 2024
Viewed by 567
Abstract
Background: It was to understand HPV vaccination patterns, uptake, perceptions, and sexual risk factors in students at a Midwest public university. Participants: Students were enrolled during the spring 2024 semester at the University of Iowa. Methods: A survey was developed and emailed to [...] Read more.
Background: It was to understand HPV vaccination patterns, uptake, perceptions, and sexual risk factors in students at a Midwest public university. Participants: Students were enrolled during the spring 2024 semester at the University of Iowa. Methods: A survey was developed and emailed to 28,095 students asking demographic, general and sexual health, and HPV-related questions. Results: The response rate was 4.9%, with 76% females and a median age of 22. The HPV vaccine uptake was 82%, with 88% recommending the vaccine. Parental preference was the main reason for being unvaccinated. The median age of sexual debut was 17 years, with a median of 2 sexual partners. Vaccination was associated with female, health science, sexually active, and COVID-19/influenza vaccinated students. Conclusions: HPV vaccine uptake at University of Iowa students is higher than the national and Iowa averages. Increased education regarding HPV vaccination is still needed, particularly in males, those not having sex, and those not receiving other vaccines. Full article
(This article belongs to the Special Issue Prevention of Human Papillomavirus and Vaccines Strategies)
►▼ Show Figures

Figure 1

Other

Jump to: Research

19 pages, 447 KiB  
Systematic Review
A Systematic Review of Human Papillomavirus Vaccination Challenges and Strategies to Enhance Uptake
by Mansour Tobaiqy and Katie MacLure
Vaccines 2024, 12(7), 746; https://doi.org/10.3390/vaccines12070746 - 6 Jul 2024
Viewed by 1618
Abstract
Human papillomavirus (HPV) vaccination has revolutionized cervical cancer prevention. Clinical trials confirm that the quadrivalent (HPV types 6, 11, 16, 18) and bivalent (HPV types 16, 18) vaccines effectively prevent HPV infections and cervical neoplasia. The latest HPV vaccine protects against nine virus [...] Read more.
Human papillomavirus (HPV) vaccination has revolutionized cervical cancer prevention. Clinical trials confirm that the quadrivalent (HPV types 6, 11, 16, 18) and bivalent (HPV types 16, 18) vaccines effectively prevent HPV infections and cervical neoplasia. The latest HPV vaccine protects against nine virus types responsible for 90% of cervical cancer cases globally. Despite their undoubted effectiveness in reducing morbidity and mortality associated with HPV infections, challenges in vaccine coverage and uptake persist. The current study aimed to identify the primary challenges associated with HPV vaccination, propose effective strategies to improve vaccination uptake, and compile relevant evidence into a comprehensive overview to inform policy and practice. A systematic review protocol, following PRISMA-P and PRISMA guidelines, was established. Articles were sourced from the Web of Science using keywords from a comprehensive review of HPV vaccination challenges and strategies. Studies published between 1 January 2020, and 1 May 2024, including RCTs and observational, qualitative, and cross-sectional studies, were included, while reviews, protocols, and commentaries were excluded. Titles, abstracts, and full texts were screened per PRISMA guidelines. The review identified five key strategies to improve HPV vaccination uptake: parental and school engagement, use of technology and multimedia tools, healthcare providers’ role, multicomponent interventions, and targeted interventions for immigrant groups. This review emphasized the need for a multifaceted approach to improving vaccination rates, offering a robust foundation for policy and stakeholder initiatives. Full article
(This article belongs to the Special Issue Prevention of Human Papillomavirus and Vaccines Strategies)
►▼ Show Figures

Figure 1

16 pages, 4089 KiB  
Systematic Review
EMR-Based Interventions on HPV Vaccination Initiation, Completion, and Receiving the Next Dose: A Meta-Analytic Review
by Nutthaporn Chandeying and Therdpong Thongseiratch
Vaccines 2024, 12(7), 739; https://doi.org/10.3390/vaccines12070739 - 3 Jul 2024
Viewed by 412
Abstract
Despite the acknowledged importance of Human Papillomavirus (HPV) vaccination in reducing HPV-related diseases, the influence of electronic medical records (EMR) on HPV vaccination uptake (HVU) remains underexplored. This study aimed to evaluate the efficacy of EMR-based interventions on HVU. A systematic review and [...] Read more.
Despite the acknowledged importance of Human Papillomavirus (HPV) vaccination in reducing HPV-related diseases, the influence of electronic medical records (EMR) on HPV vaccination uptake (HVU) remains underexplored. This study aimed to evaluate the efficacy of EMR-based interventions on HVU. A systematic review and meta-analysis of randomized controlled trials were performed, focusing on studies that primarily used EMR-based interventions to measure initiation rates, completion rates, and receipt of the next required vaccine dose. Subgroup analyses were conducted to assess the differential effects of supplementary strategies, provider feedback, and parental education or reminders on these outcomes. The results of the comprehensive analysis provided robust evidence for the significant role of EMR interventions, demonstrating an average increase of 4.7% in vaccine initiation, 6.6% in vaccine completion, and 7.2% in receipt of the next HPV vaccine dose. Additionally, the subgroup analyses indicated that provider feedback and parental education could further enhance the effectiveness of EMR-based interventions. These findings support the broader adoption of digital health technologies in vaccination programs, offering vital insights for healthcare providers, policymakers, and researchers, and emphasizing the need for continued technological innovation to improve public health outcomes. Full article
(This article belongs to the Special Issue Prevention of Human Papillomavirus and Vaccines Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop